US-based digital therapeutics company Biofourmis has signed an agreement to buy Zurich, Switzerland-based wearable biosensor company Biovotion. The deal consists of all Biovotion’s assets, including the clinical-grade Everion® device and over 60 global patents.
The acquisition of Biovotion enables Biofourmis to offer proprietary, clinical-grade wearables as part of its Biovitals® ecosystem, a highly sophisticated personalized AI-powered predictive analytics platform that predicts clinical exacerbation in advance of a critical event. The multi-parameter physiology data captured from Everion will be an integral component of Biovitals’ digital therapeutics products and pipeline to manage conditions such as heart failure, COPD, oncology and pain.
Clinical-grade wearables are becoming integral across all areas of healthcare. These wearables can help modify patient behavior, and offer continuous real-time physiological data, allowing physicians to intervene earlier. Combining Biovotion’s best-in-class wearables with Biofourmis’ digital therapeutics platform and its leading artificial intelligence (AI)-driven predictive analytics creates the most comprehensive digital therapeutics solution on the market, said Biofourmis in a press release.
“Biovotion had been a trusted partner for many years as we have leveraged each other’s technologies across numerous clinical, commercial and research applications,” said Kuldeep Singh Rajput, CEO and founder of Biofourmis. “We are thrilled to add Everion to the Biovitals® ecosystem, which will continue to help our clients achieve their goals such as demonstrating the value of pharmacotherapy, managing chronic diseases, predicting and preventing adverse events, and improving clinical outcomes—and ultimately reducing healthcare costs.”
The lead product among Biovotion’s wearables is the clinical-grade Everion device, which is a multi-sensor platform worn on the arm capable of measuring 22 parameters in real time. Collected physiological data can include heart rate, inter-beat interval, respiratory rate, blood oxygenation, skin temperature and actigraphy (rest/activity cycles)—all gathered non-invasively. Additional clinical and non-clinical parameters such as blood pulse wave, motion intensity and steps, energy expenditure, sleep quality and heart rate variability are also insights collected by Everion.
Building on Everion’s current market-leading wearable, the next-generation Everion device is already under development and will have the ability to capture additional vital parameters, including continuous blood pressure trends.
In addition to the acquisition, Biofourmis also announced a partnership with Swiss pharma company Novartis to supply patients using Entresto, a drug for reducing heart failure, with the Biofourmis platform, including Everion devices.